natgillin/translations-raw huggingface dataset:
Hvis du afbryder behandlingen med Viramune i mere end 7 dage, vil din læge råde dig til at starte igen med en 14 dages "optrapningsfase" (som beskrevet ovenfor), før du igen går over til behandling 2 gange daglig. 
If you stop taking Viramune for more than 7 days your doctor will instruct you to start the 14 day 'lead-in' period (described above) once again, before returning to the twice daily dose.
Tenofovir og Viramune kan coadministreres uden dosisjustering. 
Tenofovir and Viramune can be coadministered without dose adjustments.
Viramune tabletter indeholder mindre end 1 mmol (23 mg) natrium pr. tablet, dvs. de er i det væsentlige natrium-frie. 
Viramune tablets contain less than 1 mmol sodium (23 mg) per tablet, that is to say essentially
Anvendes senest 2 måneder efter åbning. 
The medicinal product should be used within 2 months of opening.
Det er meget vigtigt, at dit barn kun får Viramune 1 gang om dagen i de første 14 dage af behandlingen (optrapningsfasen). 
It is very important that your child takes Viramune only once a day for the first 14 days (“lead-in” period).
Itraconazole 200 mg 4 gange dagli 
Itraconazole 200 mg QD
Gulsot, fulminant hepatitis (som kan være letal) 
Uncommon jaundice, hepatitis fulminant (which may be fatal) Rare hepatitis (incl.
Er du i tvivl, så spørg lægen eller apotekspersonalet. 
If you are uncertain please be sure to ask your child's doctor or pharmacist.
Natriumstivelsesglycolat Kolloid silica 
Microcrystalline cellulose
Vedligeholdelsespakning 
Treatment initiation pack
Før du begynder at tage Viramune depottabletter, skal du have været i 14 dages behandling med enten Viramune 200 mg tabletter eller Viramune suspension, medmindre du i forvejen tager Viramune, og skifter behandling til depottabletter. 
Viramune prolonged-release tablets should only be used after a two-week treatment with another type of Viramune (immediate-release tablets or suspension) unless you are currently on Viramune and are switching to the prolonged-release form.
Nevirapin bør seponeres permanent hos enhver patient, som udvikler overfølsomhedsreaktioner (karakteriseret ved udslæt med konstitutionelle symptomer samt organpåvirkning, såsom hepatitis, eosinofili, granulocytopeni og nyresvigt) (se pkt. 
Nevirapine must be permanently discontinued in any patient experiencing hypersensitivity reaction (characterised by rash with constitutional symptoms, plus visceral involvement, such as hepatitis, eosinophilia, granulocytopenia, and renal dysfunction) see section 4.4.
Fosamprenavir 1400 mg 2 gange dagligt 
Fosamprenavir 1400 mg BID
Nevirapin bør permanent seponeres hos patienter med moderate til svære stigninger (ASAT eller ALAT > 5 ULN). 
Patients with moderate to severe elevations (ASAT or ALAT > 5 ULN) should be permanently discontinued from nevirapine.
letale tilfælde er forekommet hos patienter behandlet med nevirapin, hovedsagelig i løbet af de første 6 uger af behandlingen. 
Severe and life-threatening skin reactions, including fatal cases, have occurred in patients treated with nevirapine mainly during the first 6 weeks of therapy.
Hvis du inden for 12 timer opdager, at du har glemt en dosis, så tag den glemte dosis hurtigst muligt. 
If you notice you missed a dose within 12 hours of when it was due, take the missed dose as soon as possible.
LÆGEMIDDELFORM OG INDHOLD (PAKNINGSSTØRRELSE) 90 depottabletter 
PHARMACEUTICAL FORM AND CONTENTS 90 prolonged-release tablets
Almindelig (kan forekomme hos op til 1 ud af 10 patienter): - nedsat antal hvide blodlegemer (granulocytopeni) - allergiske reaktioner (overfølsomhed) - hovedpine - føler sig syg (kvalme) - opkastning - mavesmerter - løs afføring (diarré) - leverbetændelse (hepatitis) - udmattelse - feber - leverfunktionsprøver udenfor normalområdet 
Common (may affect up to 1 in 10 people): - decreased numbers of white blood cells (granulocytopenia) - allergic reactions (hypersensitivity) - headache - feeling sick (nausea) - vomiting - abdominal pain - loose stools (diarrhoea) - inflammation of the liver (hepatitis) - feeling tired (fatigue) - fever - abnormal liver function tests
Det anbefales ikke at coadministrer ketoconazol og Viramune (se pkt. 
It is not recommended to coadminister ketoconazole and Viramune (see section 4.4).
Viramune kan tages med eller uden mad. 
Viramune may be taken with or without food.
Cirka halvdelen af patienterne havde mindst 3 års forudgående behandling med Viramune 200 mg, før inkludering i studie 1100.1526. 
Approximately half of the patients had at least 3 years of prior exposure to Viramune immediate-release prior to entering study
MARKEDSFØRINGSTILLADELSESNUMMER (-NUMRE) EU/1/97/055/008 [30 depottabletter] 
MARKETING AUTHORISATION NUMBER(S) EU/1/97/055/008 [30 prolonged-release]
Viramune tilhører en gruppe af lægemidler, som kaldes antiretrovirale lægemidler. 
Viramune belongs to a group of medicines called antiretrovirals, used in the treatment of Human Immunodeficiency Virus (HIV-1) infection.
Saquinavir/ritonavir og Viramune kan co-administreres uden dosisjustering. 
Saquinavir/ritonavir and Viramune can be co-administered without dose adjustments.
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. dosisenhed, dvs. det er i det væsentlige natrium-frit. 
This medicine contains less than 1 mmol sodium (23 mg) per dosage unit, that is to say essentially ‘sodium-free'.
I tilfælde af virologisk svigt ved nevirapin-behandling kan der efterfølgende forventes krydsresistens til delavidin og efavirenz. 
Cross resistance to delavirdine and efavirenz is expected after virologic failure with nevirapine.
Nevirapin viste in vitro i kombination med efavirenz en stærk antagonistisk anti-hiv-1-aktivitet (se pkt. 
Nevirapine in combination with efavirenz exhibited a strong antagonistic anti-HIV-1 activity in vitro (see section 4.5) and was additive to antagonistic with the protease inhibitor ritonavir or the fusion inhibitor enfuvirtide.
Almene symptomer og reaktioner på administrationsstedet Almindelig: 
General disorders and administration site conditions Common fatigue
Rifampicin 600 mg 4 gange daglig 
Rifampicin 600 mg QD
hvis du tidligere har taget Viramune og måtte stoppe behandlingen, fordi du har fået: alvorligt hududslæt hududslæt og samtidig har andre symptomer som - feber - blæredannelse 
- if you have taken Viramune before and had to stop the treatment because you suffered from: - severe skin rash - skin rash with other symptoms for example: - fever
Abdominalsmerter, kvalme, diarré 
Gastrointestinal disorders Common abdominal pain, nausea, diarrhoea Uncommon vomiting
Vægt og metaboliske parametre: Vægtstigning og forhøjede lipider og glucose i blodet kan forekomme under antiretroviral behandling. 
An increase in weight and in levels of blood lipids and glucose may occur during antiretroviral therapy.
Hvis du får nogen form for udslæt i denne periode, må du ikke begynde at tage Viramune depottabletter. 
If you have any rash during this period, do not start taking Viramune prolonged-release tablets but consult your doctor.
Brug ikke lægemidlet efter den udløbsdato, der står på æsken og på blisteren efter ”EXP”. 
Do not use this medicine after the expiry date which is stated on the carton and on the blister after “EXP”.
Der forventes ingen interaktion på grund af mekanisme ved raltegravir metabolisme. 
Due to the metabolic pathway of raltegravir no interaction is expected.
INFORMATION I BRAILLESKRIFT viramune 400 mg depottabletter 
INFORMATION IN BRAILLE viramune 400 mg prolonged-release tablets
Det er særligt vigtigt, at du fortæller det til din læge, hvis du tager eller for nylig har taget: - perikon (Hypericum perforatum, naturlægemiddel til behandling af depression) - rifampicin (mod tuberkulose) - rifabutin (mod tuberkulose) - makrolider som clarithromycin (antibiotika) - fluconazol (mod svampeinfektion) - ketoconazol (mod svampeinfektion) - itraconazol (mod svampeinfektion) - metadon (substitut for heroin eller andre opiater) - warfarin (antikoagulant-blodfortyndende) - hormonale antikonceptionsmidler, f.eks. p-piller - atazanavir (mod hiv-infektion) - lopinavir/ritonavir (mod hiv-infektion) - fosamprenavir (mod hiv-infektion) - efavirenz (mod hiv-infektion) - etravirin (mod hiv-infektion) - rilpivirin (mod hiv-infektion) - delavirdin (mod hiv-infektion) - zidovudin (mod hiv-infektion) - boceprevir (mod hepatitis C) - telaprevir (mod hepatitis C) - elvitegravir/cobicistat (mod hiv-infektion) 
It is particularly important that you tell your doctor if you are taking or have recently taken: - St. John's Wort (Hypericum perforatum, medicine to treat depression) - rifampicin (medicine to treat tuberculosis) - rifabutin (medicine to treat tuberculosis) - macrolides e.g. clarithromycin (medicine to treat bacterial infections) - fluconazole (medicine to treat fungal infections) - ketoconazole (medicine to treat fungal infections) - itraconazole (medicine to treat fungal infections) - methadone (medicine used for treatment of opiate addicts) - warfarin (medicine to reduce blood clotting) - hormonal contraceptives (e.g. the “pill”) - atazanavir (another medicine to treat HIV-infection) - lopinavir/ritonavir (another medicine to treat HIV-infection) - fosamprenavir (another medicine to treat HIV-infection) - efavirenz (another medicine to treat HIV-infection) - etravirine (another medicine to treat HIV-infection) - rilpivirine (another medicine to treat HIV-infection) - delavirdine (another medicine to treat HIV-infection) - zidovudine (another medicine to treat HIV-infection) - boceprevir (medicine to treat hepatitis C) - telaprevir (medicine to treat hepatitis C) - elvitegravir/cobicistat (another medicine to treat HIV-infection)
D-55216 Ingelheim am Rhein, Tyskland 
55216 Ingelheim am Rhein, Germany
Tilfælde af hepatitis (alvorlig og livstruende hepatotoksicitet, inkl. 
Cases of hepatitis (severe and life-threatening hepatotoxicity, including fatal fulminant hepatitis) have been reported in patients treated with nevirapine.
De var som minimum behandlet med 200 mg Viramune tabletter med øjeblikkelig virkning 2 gange dagligt i 6 uger inden de farmakokinetiske prøver blev taget. 
The patients studied were receiving antiretroviral therapy containing Viramune 200 mg immediaterelease tablets twice daily for at least 6 weeks prior to pharmacokinetic sampling, with a median duration of therapy of 3.4 years.
Metabolit 14-OH clarithromycin AUC Metabolit 14-OH clarithromycin Cmin Metabolit 14-OH clarithromycin Cmax 
Metabolite 14-OH clarithromycin AUC  1.42 (1.16-1.73) Metabolite 14-OH clarithromycin Cmin  0 (0.68-1.49) Metabolite 14-OH clarithromycin Cmax  1.47 (1.21-1.80)
Blod og lymfesystem Ikke almindelig : 
Blood and lymphatic system disorders Uncommon granulocytopenia Rare anaemia
Hvis du afbryder behandlingen med Viramune i mere end 7 dage, vil din læge råde dig til at starte igen med en 14 dages "optrapningsfase" med Viramune oral suspension (som beskrevet ovenfor), før du igen starter på behandling med Viramune depottabletter én gang dagligt. 
If you stop taking Viramune for more than 7 days your doctor will instruct you to start the 14 day 'lead-in' period with Viramune oral suspension (described above) once again, before returning to the once daily dose with Viramune prolonged-release tablets.
4.4 og 4.5). 
31.3 to 43.7
LÆGEMIDLETS NAVN Viramune 200 mg tabletter nevirapin 
NAME OF THE MEDICINAL PRODUCT Viramune 200 mg tablets nevirapine
Viramune og abacavir kan coadministreres uden dosisjustering. 
Viramune and abacavir may be coadministered without dose adjustments.
Viramune depottabletter kan tages sammen med eller uden mad. 
Viramune prolonged-release tablets can be taken with or without food.
Følgende bivirkninger, som kan være forårsaget af Viramune depottabletter, er tidligere blevet rapporteret. 
The following adverse reactions which may be causally related to the administration of Viramune prolonged-release tablets have been reported.
I studie 1100.1486 (VERxVE) med antiretroviralnaive patienter var optrapningsdosis af Viramune 200 mg én gang dagligt i 14 dage (n=1068), hvorefter patienterne blev randomiseret til enten Viramune 200 mg tabletter to gange dagligt eller Viramune 400 mg i depotform én gang dagligt. 
In study 1100.1486 (VERxVE) antiretroviral-naïve patients received a lead-in dose of Viramune 200 mg immediate-release once daily for 14 days (n=1068) and then were randomised to receive either Viramune 200 mg immediate-release twice daily or Viramune 400 mg prolonged-release once daily.
Kvindelige patienter og patienter med høje CD4-celletal (> 250 celler/mm 
Female gender and higher CD4 counts (>250/mm
Hvis ASAT og ALAT vender tilbage til baselineværdier, og hvis patienten ikke har nogen kliniske tegn eller symptomer på hepatitis, udslæt eller andre symptomer eller fund, der tyder på organpåvirkning, er det muligt at genintroducere nevirapin efter en individuel patientvurdering, med en startdosis én gang dagligt i 14 dage af Viramune med umiddelbar frigivelse efterfulgt af Viramune depottabletter én gang dagligt. 
If ASAT and ALAT return to baseline values and if the patient had no clinical signs or symptoms of hepatitis, rash, constitutional symptoms or other findings suggestive of organ dysfunction, it may be possible to reintroduce nevirapine, on a case by case basis, at the starting dose regimen of Viramune immediate-release once daily for 14 days followed by Viramune prolonged-release tablets once daily.
Lamivudin 150 mg 2 gange daglig 
Lamivudine 150 mg BID
Viramune indeholder lactose 
Viramune contains lactose
Disse bivirkninger er ofte forbundet med andre antiretrovirale midler og vil muligvis forventes at opstå, når nevirapin anvendes i kombination med disse midler. 
These adverse reactions are commonly associated with other antiretroviral agents and may be expected to occur when nevirapine is used in combination with other agents; however it is unlikely that these adverse reactions are due to nevirapine treatment.
Hvis ASAT og ALAT vender tilbage til baselineværdier, og hvis patienten ikke har nogen kliniske tegn eller symptomer på hepatitis, udslæt eller andre symptomer eller fund, der tyder på organpåvirkning, er det muligt at genintroducere nevirapin efter en individuel patientvurdering med en startdosis på 200 mg/dag i 14 dage efterfulgt af 400 mg/dag. 
If ASAT and ALAT return to baseline values and if the patient had no clinical signs or symptoms of hepatitis, rash, constitutional symptoms or other findings suggestive of organ dysfunction, it may be possible to reintroduce nevirapine, on a case by case basis, at the starting dose regimen of 200 mg/day for 14 days followed by 400 mg/day.
Hvis du afbryder behandlingen med Viramune i mere end 7 dage, vil din læge råde dig til at starte igen med en 14 dages "optrapningsfase" med Viramune tabletter (som beskrevet ovenfor), før du igen starter på behandling med Viramune depottabletter én gang dagligt. 
If you stop taking Viramune for more than 7 days your doctor will instruct you to start the 14 day 'lead-in' period with Viramune tablets (described above) once again, before returning to the once daily dose with Viramune prolonged-release tablets.
Hvis patienter oplever træthed, skal de afstå fra at køre bil eller betjene maskiner. 
If patients experience fatigue they should avoid potentially hazardous tasks such as driving or operating machinery.
Vægtinterval (kg) for patienter ≥ 8 år med dosis beregnet efter legemsvægt. 
Weight Range (kg) for patients  8 years of age on a body weight basis receiving 4 mg/kg.
Leverfunktionstest uden for normalområdet (forhøjet alaninaminotransferase, forhøjede transaminaser, forhøjet aspartat-aminotransferase, forhøjet gamma-glutamyltransferase, forhøjet hepatisk enzym, hypertransaminasæmi), nedsat fosfor i blodet, øget blodtryk 
Uncommon liver function test abnormal (alanine aminotransferase increased; transaminases increased; aspartate aminotransferase increased; gamma-glutamyltransferase increased; hepatic enzyme increased; hypertransaminasaemia), blood phosphorus decreased, blood pressure increased
Didanosin og Viramune kan coadministreres uden dosisjustering. 
Didanosine and Viramune can be coadministered without dose adjustments.
Det anbefales ikke at coadministrer rifampicin og Viramune (se pkt. 
It is not recommended to coadminister rifampicin and Viramune (see section 4.4).
I et 200 mg nevirapine enkelt dosis farmakokinetisk studie af hiv-negative patienter med mild til moderat hepatisk dysfunktion (Child-pugh A, n=6; Child-pugh B, n=4), blev der observeret en signifikant forøgelse af nevirapine-AUC hos en Child-pugh B patient med ascites. 
In a 200 mg nevirapine single dose pharmacokinetic study of HIV-negative patients with mild and moderate hepatic impairment (Child-Pugh A, n=6; Child-Pugh B, n=4), a significant increase in the AUC of nevirapine was observed in one Child-Pugh B patient with ascites suggesting that patients with worsening hepatic function and ascites may be at risk of accumulating nevirapine in the systemic circulation.
4.4) på grund af additiv toksicitet og ingen fordel med hensyn til virkning i forhold til det enkelte NNRTI alene (for resultaterne fra 2NN-studiet, se pkt. 
It is not recommended to coadminister efavirenz and Viramune (see section 4.4), because of additive toxicity and no benefit in terms of efficacy over either NNRTI alone (for results of 2NN study, see section 5.1 Viramune immediate-release formulations).
Der var ingen statistisk signifikant forskel mellem efavirenz og ”Viramune 2 gange daglig” for hverken det primære (p = 0,92) eller det sekundære endepunkt. 
Both, the primary (p = 0.92) and secondary endpoints showed no statistically significant differences between efavirenz and Viramune 200 mg twice daily.
Nervesystemet Almindelig: 
Nervous system disorders Common headache
Du må ikke tage Viramune som den eneste behandling. 
You should not use Viramune on its own.
3 for kvinder og > 400 celler/mm 
3 in adult females and >400/mm
INFORMATION I BRAILLESKRIFT viramune 100 mg depottabletter 
INFORMATION IN BRAILLE viramune 100 mg prolonged-release tablets
Patienter, der aktuelt får Viramune 200 mg to gange dagligt: 
Patients currently on a Viramune immediate-release twice daily regimen:
Maraviroc og Viramune kan coadministreres uden dosisjustering. 
Maraviroc and Viramune can be coadministered without dose adjustments.
Udslæt opstår selvstændigt som lægemiddelreaktion med eosinifili og systemiske reaktioner, karakteriseret ved symptomer, såsom feber, ledsmerter, muskelsmerter og lymfeknudesvulster sammen organpåvirkning, såsom hepatitis, eosinofili, granulocytopeni og nyredysfunktion. 
Rashes occur alone or in the context of drug reaction with eosinophilia and systemic symptoms, characterised by rash with constitutional symptoms such as fever, arthralgia, myalgia and lympadenopathy, plus visceral involvement, such as hepatitis, eosinophilia, granulocytopenia, and renal dysfunction.
Plasmakoncentrationen for lægemidler, der metaboliseres via disse enzymsystemer kan eventuelt være nedsat når de gives samtidig med nevirapin. 
Compounds using this metabolic pathway may have decreased plasma concentrations when coadministered with nevirapine.
Nevirapinniveauet kan stige ved ophør med perikon. 
Nevirapine levels may increase on stopping St. John‘s Wort.
letal fulminant hepatitis er set hos patienter behandlet med nevirapin. 
Severe and life-threatening hepatotoxicity, including fatal fulminant hepatitis, has occurred in patients treated with nevirapine.
KVALITATIV OG KVANTITATIV SAMMENSÆTNING En depottablet indeholder 100 mg nevirapin (vandfri). 
QUALITATIVE AND QUANTITATIVE COMPOSITION Each prolonged-release tablet contains 100 mg of nevirapine (as anhydrous).
De var som minimum behandlet med 200 mg Viramune 2 gange dagligt i 6 uger inden de farmakokinetiske prøver blev taget. 
The patients studied were receiving antiretroviral therapy containing Viramune 200 mg twice daily for at least 6 weeks prior to pharmacokinetic sampling, with a median duration of therapy of 3.4 years.
Risikoen for leverpåvirkning og hudreaktioner er størst i de første 6 uger af behandlingen. 
The greatest risk of hepatic and skin reactions occurs in the first 6 weeks of therapy.
I studie 1100.1486 (VERxVE) med behandlingsnaive patienter var optrapningsdosis af Viramune 200 mg tabletter én gang dagligt i 14 dage, hvorefter patienterne blev randomiseret til enten Viramune 200 mg tabletter to gange dagligt eller Viramune 400 mg depottabletter én gang dagligt. 
In study 1100.1486 (VERxVE) treatment-naïve patients received a lead-in dose of Viramune 200 mg immediate-release once daily for 14 days and then were randomised to receive either Viramune 200 mg immediate-release twice daily or Viramune 400 mg prolonged-release once daily.
Påsæt adaptoren (ved først at presse og derefter skrue) på den åbne flaskehals. 
Shake the bottle gently Fit (by first pressing and then screwing) the adapter onto the open bottle neck Insert the syringe into the adapter Invert the bottle Withdraw the required dose volume The bottle can be kept sealed with the flexible lid of the adapter.
Atazanavir/r 400/100 mg Atazanavir/r AUC  0,81 (0,65-1,02) Atazanavir/r Cmin  0,41 (0,27-0,60) Atazanavir/r Cmax  1,02 (0,85-1,24) (sammenlignet med 300/100 mg uden nevirapin) 
Atazanavir/r AUC  0.81 (0.65-1.02) Atazanavir/r Cmin  0.41 (0.27-0.60) Atazanavir/r Cmax  1.02 (0.85
KVALITATIV OG KVANTITATIV SAMMENSÆTNING En depottablet indeholder 400 mg nevirapin (vandfri). 
QUALITATIVE AND QUANTITATIVE COMPOSITION Each prolonged-release tablet contains 400 mg of nevirapine (as anhydrous).
Resultater fra in vitro studier viste en svag antagonisme fra ribavirin på nevirapin (se pkt. 
Results of in vitro studies showed a weak antagonism of nevirapine by ribavirin (see section 5.1), this has not been confirmed in clinical trials and reduced efficacy is not expected.
I et enkeltdosis farmakokinetisk studie med Viramune 200 mg tabletter af hiv-negative patienter med mild til moderat hepatisk dysfunktion (Child-Pugh A, n=6; Child-Pugh B, n=4), blev der set en signifikant forøgelse af nevirapin-AUC hos en Child-Pugh B patient med ascites. 
In a single dose pharmacokinetic study of 200 mg Viramune immediate-release tablets in HIV-negative patients with mild and moderate hepatic impairment (Child-Pugh A, n=6; Child-Pugh B, n=4), a significant increase in the AUC of nevirapine was observed in one Child-Pugh B patient with ascites suggesting that patients with worsening hepatic function and ascites may be at risk of accumulating nevirapine in the systemic circulation.
Det anbefales ikke at coadministrere Viramune og NNRTI (se pkt. 
The concomitant administration of Viramune with NNRTIs is not recommended (see section 4.4).
Vægtinterval (kg) for patienter < 8 år med dosis beregnet efter legemsvægt. 
Weight Range (kg) for patients < 8 yrs of age on a body weight basis receiving 7 mg/kg.
Rifabutin og Viramune kan co-administreres uden dosisjustering. 
Rifabutin and Viramune can be co-administered without dose adjustments.
Stavudin 30/40 mg 2 gange dagligt 
Stavudine: 30/40 mg BID
Dosering af nevirapin med 150 mg/m² to gange dagligt (efter en to ugers indkøringsperiode med 150 mg/m² en gang dagligt) gav geometriske middelværdier eller middelværdi af trough nevirapinkoncentrationer på 4-6 µg/ml (som voksendata). 
150 mg/m2 QD) produced geometric mean or mean trough nevirapine concentrations between 46 µg/ml (as targeted from adult data).
Det aktive stof i Viramune er nevirapin. 
The active substance of your medicine is called nevirapine.
Fosamprenavir/ritonavir og Viramune kan co-administreres uden dosisjustering. 
Fosamprenavir/ritonavir and Viramune can be co-administered without dose adjustments
ALAT, ASAT, GGT, total-bilirubin og alkalisk fosfatase. 
The most frequently observed laboratory test abnormalities are elevations in liver function tests (LFTs), including ALAT, ASAT, GGT, total bilirubin and alkaline phosphatase.
ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER 1 tablet indeholder 200 mg nevirapin (vandfri) 
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 200 mg of nevirapine (as anhydrous)